Honeywell Aerospace Selected By Pilatus For PC-24 Cockpit Avionics

Posted on by

GENEVA, May 21, 2013 /PRNewswire/ --EBACE -- Honeywell (HON) has been selected by Pilatus Aircraft Ltd. to supply the avionics suite for the newly announced Pilatus PC-24 Twin Jet. A combination of components from Primus Epic and Primus Apex will provide the core functionality, safety and display content for the Pilatus Advanced Cockpit Environment (ACE), designed specifically for the PC-24.

(Logo: http://photos.prnewswire.com/prnh/20080425/LAF040LOGO)

Primus Apex is proved on several platforms including the Pilatus PC-12 NG. Drawing on functionality from Honeywell's Primus Epic flight deck, which is available for larger cabin business and regional aircraft, Primus Apex for the PC-12 NG and Pilatus ACE for the PC-24 ensure the consistency of design philosophy and operational practices throughout the Pilatus business aircraft line. Pilots will have access to safety features and operational functionality previously reserved for the most sophisticated global business jets.

Pilatus ACE Features for the PC-24 include:

Supporting Quotes

"Honeywell has long been a supporter of Pilatus by providing PC-12 NG pilots with access to the most advanced safety, autoflight, navigation and situational awareness capabilities available for turboprop planes. Building on that foundation, the Pilatus PC-24 will utilize the Pilatus ACE based on Honeywell's Primus Epic and Primus Apex flight decks, providing pilots with features and capabilities previously only found on high-end business jets."

"For our first twin jet, we wanted to make sure that the PC-24 had the latest avionics and technology to provide pilots with the safest flying experience possible. Through our work with Honeywell on the PC-12 NG, we know that Honeywell's integrated flight deck products provide pilots with safety enhancements and technology that greatly increase operational efficiency and the overall flight experience. Therefore we decided to jointly develop the unique and customized Pilatus ACE focusing on the individual needs and requirements of the future PC-24 operator."

Honeywell is showcasing its complete line of business aviation offerings at EBACE 2013 in Geneva, May 2123, at Booth #487.

Supporting Resources

Thousands of Honeywell Aerospace products and services are found on virtually every commercial, defense and space aircraft worldwide. The Aerospace business unit develops and integrates technologies that span air traffic modernization, flight and runway safety, engines, cockpit and cabin electronics, connectivity, logistics and more that deliver safe, efficient, productive and comfortable transportation-related experiences. For more information, visit http://aerospace.honeywell.com or follow us at @honeywell_aero on Twitter.

Read the original:

Honeywell Aerospace Selected By Pilatus For PC-24 Cockpit Avionics

Sports Medicine New Frontiers: Platelet-Rich-Plasma (PRP) and Stem Cell Therapy

Posted on by

CLEARWATER, Fla., May 20, 2013 /PRNewswire/ -- Sports Medicine is always at the forefront of innovative medical technology. Athletes are constantly striving to improve. Records are broken as humans run faster, jump higher, and strive for higher levels of performance. Athletes expose their bodies to more wear and tear as performance increases. Scientific training principles and diet have changed drastically over time. Technological breakthroughs have also impacted the rehabilitation process. The use of regenerative medicine has grown significantly in recent years. The popularity of Platelet-Rich-Plasma (PRP) has escalated as many high profile elite athletes from a diverse array of sports have opted for this treatment. The likes of Kobe Bryant, Rafael Nadal, and Tiger Woods garner ample press coverage when they are treated for injuries. Stem Cell Therapy becomes headlines when Peyton Manning undergoes this treatment. The goal of regenerative medicine therapies is to aid the body to heal itself. Understanding and accepting stem cell therapies for athletic injuries and sports medicine is gathering keen interest.

Dr. Dennis Lox, http://www.drlox.com a Sports and Regenerative Medicine Physician in the Tampa Bay Florida area, comments that the scientific backdrop of cell signaling and inflammatory mediators has led to a new understanding of how tissues heal. This also explains why injured tissues fail to heal, and is why the aging athlete recovers and heals more slowly than his younger counterpart. It is felt that the use of growth factors in Platelet-Rich-Plasma (PRP) is a localized cellular response to control negative repair processes and direct healing toward a positive restorative pathway. This directional approach to control repair, is more complex in stem cells, and as such, may be more effective for healing injured tissue. The stem cells are the body's repair cells that direct the necessary patterns of cellular messenger signals to target the repair process. It is not a simple chemical reaction where two chemicals react and one outcome results. There are a myriad of complicated molecules that interact to direct the repair process, and to counter the effects of a multitude of other molecules and signals regulating the breakdown or degradation of tissue. Dr. Lox points out, it is overcoming the many undesirable messages that occur with injury, whereby regenerative medicine may enhance sports injury recovery. Athletes are in need of rapid recovery to avoid losing peak conditioning. Aging athletes do not heal as effectively. Finding successful measures to aid the body in the healing naturally, is desirable for athletes and in preventing degenerative arthritis. Understanding the scientific rationale for the use of Platelet-Rich-Plasma (PRP) and Stem Cell Therapy, may pave the way for the expansive role for these treatments in future directions for athletic injury.

About Dr. Dennis Lox Dr. Lox practices in the Tampa Bay Florida area. Dr. Lox is a Sports and Regenerative Medicine Physician, who specializes in the use of regenerative and restorative medicine to assist in treating athletic and arthritis conditions. Dr. Lox may be reached at (727) 462-5582 or visit Drlox.com.

More here:
Sports Medicine New Frontiers: Platelet-Rich-Plasma (PRP) and Stem Cell Therapy

Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013

Posted on by

SAN DIEGO, May 20, 2013 /PRNewswire/ --Volcano Corporation (VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will highlight its efforts to expand research and innovation surrounding its physiology technologies, including its Fractional Flow Reserve (FFR) and iFR (Instant Wave-Free Ratio)1 technologies, via various clinical and educational presentations and events at EuroPCR 2013 in Paris.

"Volcano is committed to making clinical and technological advances that expand access to functional management," commented Michele Perrino, president of Europe, Middle East, Africa, and India Operations of Volcano. "Our focus at EuroPCR is to introduce our latest functional management technologies and clinical data, and demonstrate their potential to improve both patient care and the experience for our physician partners in Europe. Given our commitment to provide physicians with choice, we are excited to feature iFR, our novel hyperemia-free software modality, and our Verrata Pressure Guide Wire, which upon regulatory clearance will be our fifth new guide wire in five years."2

Volcano will formally launch its iFR modality and CORE Integrated System, and display the Verrata Wire at the conference. Volcano will showcase its future and currently available physiology, imaging, and multi-modality systems products in the company's exhibit hall booth #M71.

Featured events for Volcano include four live case symposia demonstrating the benefits of incorporating both FFR and our iFR modality in simple and complex cases, the presentation of the findings from the Adenosine Vasodilator Independent Stenosis Evaluation II (ADVISE II) study data at a hot line session, and over 10 scientific podium presentations featuring advanced physiology using Volcano products.

Key EventsWednesday, May 22, 10:50 11:30 a.m. Complex bifurcation stenting: LIVE demonstration of emerging techniquesLIVE iFR demonstration from Erasmus University Medical Center, Thorax Center Rotterdam, The Netherlands Theatre Bleu

Thursday, May 23, 9:45 - 11:45 a.m. Adenosine Vasodilator Independent Stenosis Evaluation II (ADVISE II)Hot Line - Evolving procedural strategies Room 351

Thursday, May 23, 4:45 6:45 p.m. Physiological Stenosis Assessment with FFR and Instant Wave-Free Ratio: We Need Both!Live case demonstrations (simple and multivessel disease) from St. Thomas' Hospital, London, followed by panel discussions Theatre Bordeaux

Friday, May 24, 9:00 12:30 p.m. Complex cardiovascular interventions and new techniques Master LIVE demonstrations Continuous LIVE FFR and iFR demonstrations from Sunninghill and Sunward Park Hospitals, South Africa and St Thomas' Hospital London, United Kingdom Main Arena

Daily, 12:00 3:00 p.m. Meet the iFR Experts Booth #M71

About Volcano Corporation Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Its products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.

See more here:
Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013

Resistance to last-line antibiotic makes bacteria resistant to immune system

Posted on by

Public release date: 21-May-2013 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Bacteria resistant to the antibiotic colistin are also commonly resistant to antimicrobial substances made by the human body, according to a study in mBio, the online open-access journal of the American Society for Microbiology. Cross-resistance to colistin and host antimicrobials LL-37 and lysozyme, which help defend the body against bacterial attack, could mean that patients with life-threatening multi-drug resistant infections are also saddled with a crippled immune response. Colistin is a last-line drug for treating several kinds of drug-resistant infections, but colistin resistance and the drug's newfound impacts on bacterial resistance to immune attack underscore the need for newer, better antibiotics.

Corresponding author David Weiss of Emory University says the results show that colistin therapy can fail patients in two ways. "The way that the bacteria become resistant [to colistin] allows them to also become resistant to the antimicrobials made by our immune system. That is definitely not what doctors want to do when they're treating patients with this last line antibiotic," says Weiss.

Although it was developed fifty years ago, colistin remains in use today not so much because it's particularly safe or effective, but because the choices for treating multi-drug resistant Acinetobacter baumannii and other resistant infections are few and dwindling. Colistin is used when all or almost all other drugs have failed, often representing a patient's last hope for survival.

Weiss says he and his colleagues noted that colistin works by disrupting the inner and outer membranes that hold Gram-negative bacterial cells together, much the same way two antimicrobials of the human immune system, LL-37 and lysozyme, do. LL-37 is a protein found at sites of inflammation, whereas lysozyme is found in numerous different immune cells and within secretions like tears, breast milk, and mucus, and both are important defenses against invading bacteria. Weiss and his collaborators from Emory, the CDC, Walter Reed Army Institute of Research, and Grady Memorial Hospital in Atlanta set out to find whether resistance to colistin could engender resistance to attack by LL-37 or lysozyme.

Looking at A. baumannii isolates from patients around the country, they noted that all the colistin-resistant strains harbored mutations in pmrB, a regulatory gene that leads to the modification of polysaccharides on the outside of the cell in response to antibiotic exposure. Tests showed a tight correlation between the ability of individual isolates to resist high concentrations of colistin and the ability to resist attacks by LL-37 or lysozyme.

This was very convincing, write the authors, that mutations in the pmrB gene were responsible for cross-resistance to LL-37 and lysozyme, but to get closer to a causative link between treatment and cross-resistance, they studied two pairs of A. baumannii isolates taken from two different patients before and after they were treated for three or six weeks with colistin. The results helped confirm the cross-resistance link: neither strain taken before treatment was resistant to colistin, LL-37, or lysozyme, but the strains taken after treatment showed significant resistance to colistin and lysozyme. (One post-colistin isolate was no more or less resistant to LL-37 than its paired pre-colistin isolate.) Like the resistant strains tested earlier, both post-colistin isolates harbored crucial mutations in the pmrB gene that apparently bestow the ability to resist treatment.

The authors point out that the apparent link between resistance to colistin and cross-resistance to antimicrobial agents of the immune system could well extend to other pathogens that are treated with colistin, including Pseudomonas aeruginosa and Klebsiella pneumoniae. Weiss says he plans to follow up with studies to determine whether this bears out.

For Weiss, the problems with colistin are symptomatic of a much larger trio of problems: increasing levels of drug resistance, cuts in federal funding for antibiotic research, and lack of incentives for pharmaceutical companies to invest in antibiotic R&D. "We don't have enough antibiotics, and it's really important for the research community and the public to support increases in funding for research to develop new antibiotics," says Weiss.

Visit link:
Resistance to last-line antibiotic makes bacteria resistant to immune system

Food laboratory accuracy remains a concern

Posted on by

Public release date: 20-May-2013 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Food microbiology laboratories continue to submit false negative results and false positive results on a routine basis. A retrospective study of nearly 40,000 proficiency test results over the past 14 years, presented today at the 113th General Meeting of the American Society for Microbiology, examined the ability of food laboratories to detect or rule out the presence of Escherichia coli O157:H7, Salmonella, Listeria monocytogenes, and Campylobacter.

"There is concern when laboratories report that pathogens are not found in a food sample, when in fact they are there," explained Christopher Snabes, lead author on the study. "This is known as a 'false negative'. Similar concerns arise when a laboratory reports a 'false positive' suggesting that pathogens are in the food sample, when indeed they are not."

The study found that, on average, food laboratories report false negatives of 9.1% for Campylobacter, a bacterial foodborne illness that may cause bloody diarrhea, cramping and fever, and 4.9% for Salmonella, a bacteria that may cause diarrhea, fever and abdominal cramps sometimes leading to hospitalization or death. The false positive rate, on average, is 3.9% for Salmonella, and 2.5% for both E. coli and L. monocytogenes.

This study was conducted by the American Proficiency Institute (API) located in Traverse City, Michigan. API is a private institute that supplies proficiency testing programs for food laboratories and clinical laboratories.

API offers proficiency testing (PT) as an objective method for measuring the accuracy of a laboratory. Participants use API PT up to three times a year to examine the accuracy of their laboratory personnel and their testing methods. The purpose of PT is to determine if the laboratory professional can properly respond to API with correct answers as to what API places in a food sample. PT may test for presence or absence of a substance in a qualitative test, and sometimes PT may require an enumeration response, or quantitative test.

Currently, food laboratories are not required to assess the accuracy or quality of their tests. Laboratories that utilize API PT are doing so voluntarily. Some laboratories use API services to obtain and maintain accreditation. API food microbiology PT programs are used by over 700 food laboratories in 43 countries.

Proficiency testing is an objective means for measuring laboratory accuracy. "Improved accuracy in our nation's food laboratories will lead to a safer food supply," noted Snabes.

The Food Safety Modernization Act, passed in 2011, included sweeping changes to the country's food safety requirements. Model laboratory standards and laboratory accreditation are addressed as important components of the law. Once rules are promulgated, it is anticipated that all food laboratories will need to ensure that their personnel, and the test methods they use, are in compliance with the law. Yet, food laboratories may start using proficiency testing now to help ensure a safer food product.

Continued here:
Food laboratory accuracy remains a concern

Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for …

Posted on by

MOUNTAIN VIEW, Calif., May 20, 2013 /PRNewswire-iReach/ -- Today at American Society for Microbiology conference, award lecturer Dr. Christine Ginocchio discussed Specific Technologies blood culture system as an upcoming solution for rapid identification of microorganisms producing bloodstream infection. Dr. Ginocchio is the Senior Medical Director and Chief of the Division of Infectious Disease Diagnostics at North Shore-LIJ Health System, the nation's 2nd largest not-for-profit, non-sectarian health system.

(Photo: http://photos.prnewswire.com/prnh/20130520/CG16829)

At the BD Award for Research in Clinical Microbiology presentation "Rapid Detection and Identification of Blood Stream Pathogens" Dr. Ginocchio described the groundbreaking Specific Technologies solution that identifies microorganisms during culture. Current standard practice requires completion of a blood culture and then requires additional time consuming and expensive molecular or chemical analysis. The Specific Technologies solution has demonstrated detection of infection and identification of species in blood culture 4-fold faster than the industry standard technology leading to early intervention that can save lives, with less lab labor and no additional instruments.

Bloodstream infection causing sepsis is the 10th leading cause of death, responsible for 11% of ICU admissions, with a mortality rate estimated at 28% to 50%, adding up to $50K costs per patient. To determine blood infection worldwide more than 150 million blood cultures are performed annually. Time is of the essence, survival rates decrease every hour without effective antibiotic treatment. Current blood culture practice typically takes 2 to 3 days before results can guide the effective antibiotic choice.

Dr. Ginocchio remarked, "During growth in culture bacteria produce small molecule volatile metabolites unique to their species and strain. The Specific Technologies system for identifying the microorganism from its metabolomic signature is an exciting new technology that can save precious hours critical to effective treatment of bloodstream infection causing sepsis."

Ray Martino a founder and COO of Specific Technologies, commented, "Current blood culture systems can only indicate the presence or absence of bacteria, with no information regarding ID. Not only does the Specific Tech system provide ID during culture but analytical studies have shown ID is provided more than 20% faster than current systems simply detect a positive presence."

Mr. Martino continued "We appreciate the consideration of Dr. Ginocchio a widely recognized expert in microbiology and infectious disease attested to by her track record of research and clinical leadership and advisory positions to the FDA, NIH, and IDSA, her grants, and her invited talks."

About Specific Technologies

Specific Technologies has developed in vitro diagnostic systems for rapid identification of microorganisms to diagnose infections that lead to serious medical conditions including sepsis. The company's unique, patented, metabolomic signature technology identifies microorganisms during culture growth before existing technologies based on molecular or chemical tests can be deployed resulting in faster diagnosis with less labor and no additional instruments. Specific Technologies is located in Mountain View, CA.

For additional information on the Company, please visit http://www.specifictechnologies.net .

View original post here:
Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for ...

Nicolas Cartier Appointed Corporate Vice President, Industrial Microbiology Unit of bioMérieux

Posted on by

Regulatory News :

A major player in the field of in vitro diagnostics and world leader in industrial microbiology, bioMrieux (Paris:BIM) has announced the appointment of Nicolas Cartier as Corporate Vice President, Industrial Microbiology Unit, effective starting today.

Before joining bioMrieux, Nicolas Cartier, spent most of his professional career at Sanofi. Since 2009, he has been General Manager of Sanofi France, the Groups second largest affiliate. Prior to that, he gained 10 years international experience through various roles in particular in Thailand, where he was in charge of commercial development for the Southeast Asia region within the Animal Health Division, in Shanghai, where he headed up Sanofi Chinas Pharmaceutical Division and in Mexico City, where he was General Manager of Sanofi Mexico. In France, Nicolas Cartier was Chief of Staff in the office of the Chairman and CEO of Sanofi France and then Business Unit Manager.

Nicolas Cartier will be a member of bioMrieuxs Management Committee, reporting directly to Jean-Luc Belingard, Chairman and CEO of bioMrieux.

"I am delighted to welcome Nicolas Cartier, said Jean-Luc Belingard. "He will successfully pilot our ambitious strategy in industrial microbiology, one of our most promising fields of specialization. His international experience and his knowledge of the pharmaceutical sector will represent valuable assets, enabling bioMrieux to meet the current challenges our customers have to face in industry in order to guarantee the safety and quality of their agri-food, pharmaceutical and cosmetic products worldwide.

With over 20 years expertise in industrial microbiological control, bioMrieux provides diagnostic solutions for customers in the agri-food, pharmaceutical and cosmetic industries. In 2012, the Company launched a new veterinary diagnostics activity with the aim of developing solutions to combat animal diseases and zoonoses while contributing to the prudent use of antibiotics in veterinary medicine. Today, bioMrieux offers the largest microbiological control product range on the market, and industrial applications account for more than 20% of the Groups business. Over 200 employees* contribute to building the success of the Industrial Microbiology Unit, which combines research and marketing activities to ensure the competitiveness of our commercial offering and support the development of the laboratories we serve.

* full-time equivalent

About the Industrial Microbiology Unit:

bioMrieux offers the broadest range of solutions for industrial microbiological control with both manual and automated methods to provide rapid, reliable results for the agri-food, biopharmaceutical and cosmetic industries. This range provides solutions to cover every step of microbiological analysis, from sample preparation through to final microorganism identification.

About bioMrieux

Originally posted here:
Nicolas Cartier Appointed Corporate Vice President, Industrial Microbiology Unit of bioMérieux

Longevity Medical Aesthetics — Hydrafacial Treatment — Vancouver Island – Video

Posted on by


Longevity Medical Aesthetics -- Hydrafacial Treatment -- Vancouver Island
The HydraFacial trade; The HydraFacial trade; resurfacing procedure thoroughly cares for your skin, providing cleansing, exfoliation, extractions, and hydration, includi...

By: LongevityAesthetics

See more here:
Longevity Medical Aesthetics -- Hydrafacial Treatment -- Vancouver Island - Video

Wood County celebrates longevity

Posted on by

BY KELLY McLENDON BLADE STAFF WRITER

BOWLING GREEN For Margaret Davis, 94, and Fern Sipe, 101, longevity seems to run in the family.

The Bowling Green sisters attended the 90 Plus Spectacular hosted by the Wood County Committee on Aging on Monday.

The celebration, which honored more than 60 area residents who are more than 90 years of age, brought about 100 people to the event at St. Marks Lutheran Church in Bowling Green.

Ms. Sipe, who was the oldest person at the event, said she and her sister were known for being magicians and performing for children at birthdays and other events.

She said the help of her younger sister was instrumental in pulling off performances.

I couldnt do it all, she said.

Danielle Brogley, director of programs for the Wood County Committee on Aging, said this is the third year for the event.

We do it in honor of Older Americans Month. We do it as a tribute to their lives, she said.

Ms. Brogley said many people in the community are living longer.

Read the rest here:
Wood County celebrates longevity

Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief Medical Officer

Posted on by

MORRISVILLE, N.C.--(BUSINESS WIRE)--

Oxygen Biotherapeutics, Inc. (OBI) (OXBT), today announced Col. (ret.) Charles L. Pamplin III, M.D., was appointed to the position of Chief Medical Officer effective May 20. In this position, he reports to the Chief Executive Officer. Dr. Pamplin will be implementing the Companys strategic clinical development plan. His responsibilities will include overseeing Clinical Development of Oxycyte, OBIs lead product candidate currently in Phase IIb clinical trials in Israel and Switzerland for traumatic brain injury, as well as preclinical studies here in the U.S.

At this stage, the board felt it is was important to elevate the medical and product development expertise of the company as we push through our Phase IIb clinical trials and gather the data necessary to answer the FDA questions regarding Oxycyte, said Michael Jebsen, Interim CEO and Chief Financial Officer. We believe Dr. Pamplins expertise in drug development, the drug approval process, investor outreach, and strategy, as well as his military ties will prove highly beneficial to the company immediately, and over the long term.

Most recently, Dr. Pamplin has been serving as president of Medicines Oracle, a medical consultancy to the pharmaceutical industry. Prior to that, he was Vice President of Clinical Development at King Pharmaceuticals, Inc., which has been acquired by Pfizer Inc. From May 2000 to March 2007 he was Vice President, Medical Affairs, at King. At King he contributed to the development of various adenosine receptor agonists, antagonists, and allosteric modifiers. He contributed to the development of Estrasorb, bremelanotide, Remoxy, Vanquix, Corvue, and sonodenoson and to the life cycle development of Altace, Levoxyl, and Cytomel. Prior to joining King Pharmaceuticals, he was Vice President of Quintiles Americas Internal Medicine Business Unit. He managed numerous medical specialty programs at Quintiles including womens health, urology, and dermatology.

Dr. Pamplin is a licensed and board certified physician and a retired U.S. Army Colonel (Medical Corps), specializing in Internal Medicine, Clinical Pharmacology, Business Management, and Medical Informatics. During his 22 year distinguished military career he contributed to the development of anti-malarial, antileishmanial, and chemical defense drugs and devices. He developed prophylactic and therapeutic drug treatments and strategies. In addition, he has received several military awards and honors, including the Legion of Merit, the National Defense Service Medal, and the Army Achievement Medal among others.

After receiving his medical degree from the University of Maryland, he completed his internship and residency in Internal Medicine at Walter Reed Medical Center and his post-graduate training in Clinical Pharmacology at Walter Reed Institute of Research, in Washington, D.C. He is a graduate of the Command and General Staff College. He received his undergraduate degree from Wake Forest University.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the Company has commercialized its Dermacyte line of skin care cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor Cosmetics of Switzerland.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the companys judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current Form 10-Q filed on March 18, 2013, and our annual report on Form 10-K filed on July 24, 2012, as well as other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Read more:
Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief Medical Officer